Paxlovid

A recent, scary article in the Boston Globe proclaimed the following:

About two months ago, when Pfizer's Paxlovid (1) was first distributed to a very select group of pharmacies throughout the US, you pretty much had to know the Pope (and perhaps his pharmacist) to get your hands the

During his State of the Union Address last week, President Biden announced a plan to make it easier for people to get access to the new antiviral drug Paxlovid.

The White House just announced a "test to treat" program that is an excellent, but not perfect, way of dealing with future COVID infections.

I recently wrote an article comparing the availability and use of the two newly approved anti-COVID drugs (1) Paxlovid and molnupiravir. Bottom line: Doctors and patients voted with their scripts.

Just for laughs (and what could possibly be more fun than this?), I called a bunch of local pharmacies to see whether any of them had a supply of the two newly-approved (1) antiviral COVID medications.

The Food and Drug Administration recently granted Emergency Use Authorization (EUA) to Paxlovid and molnupiravir, two lifesaving, direct-acting antiviral drugs that are effective in preventing both hospitalization and death of people who have cont

Following the FDA's granting of Emergency Use Authorization to Merck's molnupiravir and Pfizer's Paxlovid, the only two approved direct-acting antiviral drugs; we now have two badly needed tools to deal with COVID, especially since it is

Today, NBC News managed to spoil the coming-out party of a desperately needed, lifesaving drug with its lead headline of the morning: "Pfizer antiviral pills may be risky with other medications."

It's not totally absurd to compare our war against COVID with a boxing match. The virus clearly won Round 1; aside from masks and isolation, we were pretty much defenseless.